ASH: Focus on Lymphoma
Advertisement
Tycel Phillips, MD, of the City of Hope, talks about the TRIANGLE study and frontline therapy in mantle cell lymphoma.
Neha Mehta-Shah, MD, MSCI, discusses bispecific antibodies in B-cell lymphomas.
The phase II ELM-2 study showed odronextamab had “meaningful clinical efficacy” in patients with relapsed/refractory ...
Advances in treatment have led to improved outcomes in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Age and diagnosis were key predictors of whether a patient with non-Hodgkin lymphoma would participate in a clinical trial.
A novel risk estimate scale that can be used to measure survival in patients with non-Hodgkin lymphoma has been proposed.
Giovanni Manfredi Assanto discusses research on anti-SARS-CoV-2 monoclonal antibodies in patients with lymphoma and COVID-19.
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Survivors of lymphoma are at risk for the development of a second primary malignancy, including new lymphomas.
The bispecific antibody odronextamab had “compelling” efficacy in patients with relapsed or refractory follicular ...
A real-world study showed R-DA-EPOCH is “highly effective regimen” to treat primary mediastinal large B-cell lymphoma.
Ukrainians newly diagnosed with lymphoma have experienced a “dramatic” decrease in access to specialized care since the ...
Selinexor plus rituximab, gemcitabine, cisplatin and dexamethasone had encouraging activity in patients with B-cell lymphoma.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.